86541-75-5
Chemical Structure
Benazepril
Synonym(s): CGS14824A free base
- CAS No.: 86541-75-5
- Formula:C24H28N2O5
- Molecular Weight:424.49
IUPAC Name: 2-((S)-3-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid
InChIKey: XPCFTKFZXHTYIP-PMACEKPBSA-N
SMILES: O=C1N(CC(O)=O)C2=CC=CC=C2CC[C@@H]1N[C@@H](CCC3=CC=CC=C3)C(OCC)=O
Biological Activity: Benazepril (CGS14824A free base) is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. Benazepril improves diabetic nephropathy and decreases proteinuria. Benazepril can be used in the study of hypertension, heart failure and diabetic nephropathy[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Benazepril | 99.85% | Benazepril (CGS14824A free base) is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. Benazepril improves diabetic nephropathy and decreases proteinuria. Benazepril can be used in the study of hypertension, heart failure and diabetic nephropathy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Benazepril (Standard) | ≥98% | Benazepril (Standard) is the analytical standard of Benazepril. This product is intended for research and analytical applications. 0 | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hou FF, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006 Jan 12;354(2):131-40. [Content Brief]
- [2]. Huang XM, et al. Effects of chronotherapy of benazepril on the diurnal profile of RAAS and clock genes in the kidney of 5/6 nephrectomy rats. J Huazhong Univ Sci Technolog Med Sci. 2013 Jun;33(3):368-74. [Content Brief]
